AVDL - Avadel Pharmaceuticals plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 587.04M
Enterprise Value 3124.11M
Trailing P/E N/A
Forward P/E 1-3.11
PEG Ratio (5 yr expected) 10.25
Price/Sales (ttm)1.01
Price/Book (mrq)N/A
Enterprise Value/Revenue 31.44
Enterprise Value/EBITDA 6-2.48

Trading Information

Stock Price History

Beta (3Y Monthly) 1.42
52-Week Change 3-68.44%
S&P500 52-Week Change 37.06%
52 Week High 37.0200
52 Week Low 31.0300
50-Day Moving Average 32.3934
200-Day Moving Average 32.0166

Share Statistics

Avg Vol (3 month) 3351.99k
Avg Vol (10 day) 3198.93k
Shares Outstanding 537.36M
Float 26.19M
% Held by Insiders 12.74%
% Held by Institutions 155.90%
Shares Short (Jun 28, 2019) 45.95M
Short Ratio (Jun 28, 2019) 411.08
Short % of Float (Jun 28, 2019) 4N/A
Short % of Shares Outstanding (Jun 28, 2019) 415.93%
Shares Short (prior month May 31, 2019) 44.92M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019


Profit Margin -111.19%
Operating Margin (ttm)-64.64%

Management Effectiveness

Return on Assets (ttm)-13.29%
Return on Equity (ttm)-248.05%

Income Statement

Revenue (ttm)86.41M
Revenue Per Share (ttm)2.33
Quarterly Revenue Growth (yoy)-50.60%
Gross Profit (ttm)85.75M
EBITDA -50.04M
Net Income Avi to Common (ttm)-96.09M
Diluted EPS (ttm)-2.5950
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)79.85M
Total Cash Per Share (mrq)2.14
Total Debt (mrq)122.15M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)3.27
Book Value Per Share (mrq)-0.26

Cash Flow Statement

Operating Cash Flow (ttm)-85.91M
Levered Free Cash Flow (ttm)-90.76M